6Y3C image
Entry Detail
PDB ID:
6Y3C
Keywords:
Title:
Human COX-1 Crystal Structure
Biological Source:
Source Organism:
PDB Version:
Deposition Date:
2020-02-18
Release Date:
2020-02-26
Method Details:
Experimental Method:
Resolution:
3.36 Å
R-Value Free:
0.26
R-Value Work:
0.20
R-Value Observed:
0.21
Space Group:
P 65 2 2
Macromolecular Entities
Polymer Type:polypeptide(L)
Description:Prostaglandin G/H synthase 1
Chain IDs:A
Chain Length:576
Number of Molecules:1
Biological Source:Homo sapiens
Ligand Molecules
Primary Citation
Three-dimensional structure of human cyclooxygenase (hCOX)-1.
Sci Rep 11 4312 4312 (2021)
PMID: 33619313 DOI: 10.1038/s41598-021-83438-z

Abstact

The beneficial effects of Cyclooxygenases (COX) inhibitors on human health have been known for thousands of years. Nevertheless, COXs, particularly COX-1, have been linked to a plethora of human diseases such as cancer, heart failure, neurological and neurodegenerative diseases only recently. COXs catalyze the first step in the biosynthesis of prostaglandins (PGs) and are among the most important mediators of inflammation. All published structural work on COX-1 deals with the ovine isoenzyme, which is easier to produce in milligram-quantities than the human enzyme and crystallizes readily. Here, we report the long-sought structure of the human cyclooxygenase-1 (hCOX-1) that we refined to an R/Rfree of 20.82/26.37, at 3.36 Å resolution. hCOX-1 structure provides a detailed picture of the enzyme active site and the residues crucial for inhibitor/substrate binding and catalytic activity. We compared hCOX-1 crystal structure with the ovine COX-1 and human COX-2 structures by using metrics based on Cartesian coordinates, backbone dihedral angles, and solvent accessibility coupled with multivariate methods. Differences and similarities among structures are discussed, with emphasis on the motifs responsible for the diversification of the various enzymes (primary structure, stability, catalytic activity, and specificity). The structure of hCOX-1 represents an essential step towards the development of new and more selective COX-1 inhibitors of enhanced therapeutic potential.

Legend

Protein

Chemical

Disease

Primary Citation of related structures